Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook to 2023 – Astellas Pharma, Eli Lilly, GlaxoSmithKline, Sanofi, ADC Therapeutics, Bayer HealthCare, Bristol-Myers Squibb, Valeant Pharmaceuticals, Endo Pharmaceuticals, Foresee Pharmaceuticals

Nov 2018, New York USA (News)- Over the next five years, Research Reports Inc. projects that Benign Prostatic Hyperplasia (BPH) Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017..
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH.

Request for Sample of Global c Market 2018 Research Report @ https://www.researchreportsinc.com/sample-request?id=180524

Major Market Players
• Ethicon
• Pfizer
• Baxter International
• C. R. Bard
• The Medicines Company
• Anika Therapeutics
• Advanced Medical Solutions
• Integra LifeSciences
• B Braun Melsungen
• Gelita Medical
• Equimedical
• Vascular Solutions
• Marine Polymer Technologies
• Z-Medica
• CryoLife
• BioCer Entwicklungs
• Biom’Up SAS

If Have any Question or want Customized Report Click Here: https://researchreportsinc.com/enquiry?id=180524

To calculate the market size, Research Reports Inc. considers value generated from the sales of the following segments:
Segmentation by product type:
• Alpha-Blocker
• Phosphodiesterase Type-5 Inhibitors
• 5-Alpha-Reductase Inhibitors
Segmentation by application:
• Men
• Women

Directly Purchase Corporate Report with 20% Discount (Use Code “DISC20”): https://researchreportsinc.com/checkout/?add-to-cart=180524&&attribute_pa_choose-license=single-user&&quantity=1

Table of Contents
2018-2023 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report (Status and Outlook)
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2013-2023
2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Size CAGR by Region
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
2.2.1 Generic Drugs
2.2.2 Branded Drugs
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Type (2013-2018)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (2013-2018)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
2.4.1 Air Shipping
2.4.2 Sea Shipping
2.4.3 Road Shipping
2.4.4 Rail Shipping
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Application (2013-2018)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application (2013-2018)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs by Players
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Players
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Players (2016-2018)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Players (2016-2018)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Benign Prostatic Hyperplasia (BPH) Drugs by Regions
4.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Regions
4.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth
4.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth
4.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth
4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth

About Us:
Research Reports Inc. is one of the leading destinations for market research reports across all industries, companies, and technologies. Our repository features an exhaustive list of market research reports from thousands of publishers worldwide.

Contact Us:
David
Sales Manager,
US / Canada Toll Free: +18554192424
UK: +4403308087757
Email: sales@researchreportsinc.com

This release was published on openPR.